Celltex-AdMSCs
/ Celltex
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
27
Go to page
1
2
April 18, 2023
Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis
(clinicaltrials.gov)
- P1/2 | N=54 | Not yet recruiting | Sponsor: Celltex Therapeutics Corporation | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2023 ➔ Dec 2024
Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP
April 18, 2023
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
(clinicaltrials.gov)
- P2 | N=300 | Not yet recruiting | Sponsor: Celltex Therapeutics Corporation | Trial completion date: Aug 2025 ➔ Aug 2026 | Trial primary completion date: Aug 2023 ➔ Aug 2024
Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology
April 18, 2023
AdMSCs: Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
(clinicaltrials.gov)
- P2 | N=30 | Not yet recruiting | Sponsor: Celltex Therapeutics Corporation | Trial completion date: Nov 2025 ➔ Nov 2026 | Trial primary completion date: Nov 2023 ➔ Nov 2024
Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
April 18, 2023
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19
(clinicaltrials.gov)
- P2 | N=200 | Not yet recruiting | Sponsor: Celltex Therapeutics Corporation | Trial completion date: Sep 2025 ➔ Sep 2026 | Trial primary completion date: Sep 2023 ➔ Sep 2024
Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • CRP • CXCL8 • IL10 • IL6
May 06, 2022
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
(clinicaltrials.gov)
- P2 | N=300 | Not yet recruiting | Sponsor: Celltex Therapeutics Corporation | Trial completion date: Aug 2024 ➔ Aug 2025 | Trial primary completion date: Aug 2022 ➔ Aug 2023
Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology
May 05, 2022
Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis
(clinicaltrials.gov)
- P1/2 | N=54 | Not yet recruiting | Sponsor: Celltex Therapeutics Corporation | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2022 ➔ Dec 2023
Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP • TNFA
May 05, 2022
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19
(clinicaltrials.gov)
- P2 | N=200 | Not yet recruiting | Sponsor: Celltex Therapeutics Corporation | Trial completion date: Sep 2024 ➔ Sep 2025 | Trial primary completion date: Sep 2022 ➔ Sep 2023
Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • CRP • CXCL8 • IL10 • IL1B • IL6 • TNFA
April 29, 2022
AdMSCs: Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
(clinicaltrials.gov)
- P2 | N=30 | Not yet recruiting | Sponsor: Celltex Therapeutics Corporation | Trial completion date: Nov 2024 ➔ Nov 2025 | Initiation date: Nov 2021 ➔ Nov 2022 | Trial primary completion date: Nov 2022 ➔ Nov 2023
Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
August 23, 2021
AdMSCs: Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
(clinicaltrials.gov)
- P2; N=30; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation
Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease
August 18, 2021
Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis
(clinicaltrials.gov)
- P1/2; N=54; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Trial completion date: Jun 2024 ➔ Dec 2024; Trial primary completion date: Jun 2022 ➔ Dec 2022
Clinical • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP • TNFA
August 18, 2021
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19
(clinicaltrials.gov)
- P2; N=200; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Trial primary completion date: Jun 2022 ➔ Sep 2022
Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • CRP • CXCL8 • IL10 • IL1B • IL6 • TNFA
April 23, 2021
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19
(clinicaltrials.gov)
- P2; N=200; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Trial completion date: Jan 2024 ➔ Jun 2024; Trial primary completion date: Jan 2022 ➔ Jun 2022
Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • CRP • CXCL8 • IL10 • IL6
April 23, 2021
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
(clinicaltrials.gov)
- P2; N=300; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Trial completion date: Jan 2024 ➔ Jun 2024; Initiation date: Jan 2021 ➔ Jun 2021; Trial primary completion date: Jan 2022 ➔ Jun 2022
Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology • MRI
April 23, 2021
Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis
(clinicaltrials.gov)
- P1/2; N=54; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Trial completion date: Jan 2024 ➔ Jun 2024; Trial primary completion date: Jan 2022 ➔ Jun 2022
Clinical • Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP
December 19, 2019
Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis
(clinicaltrials.gov)
- P1/2; N=54; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Trial primary completion date: Dec 2022 ➔ Dec 2021
Clinical • Trial primary completion date • Immunology • Rheumatoid Arthritis • Rheumatology • CRP
November 20, 2019
Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis
(clinicaltrials.gov)
- P1/2; N=54; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation
Clinical • New P1/2 trial • Immunology • Rheumatoid Arthritis • Rheumatology • CRP
July 23, 2020
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
(clinicaltrials.gov)
- P2; N=300; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Trial completion date: Sep 2021 ➔ Jan 2022; Trial primary completion date: Aug 2020 ➔ Dec 2021
Clinical • Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology • MRI
June 11, 2020
Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis
(clinicaltrials.gov)
- P1/2; N=54; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Initiation date: Feb 2020 ➔ Jul 2020
Clinical • Trial initiation date • Immunology • Rheumatoid Arthritis • Rheumatology • CRP
June 25, 2020
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
(clinicaltrials.gov)
- P2; N=300; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation
Clinical • New P2 trial • Immunology • Osteoarthritis • Pain • Rheumatology • MRI
November 09, 2020
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19
(clinicaltrials.gov)
- P2; N=200; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Trial completion date: Jan 2022 ➔ Jan 2024
Clinical • Trial completion date • Infectious Disease • Novel Coronavirus Disease • CRP • CXCL8 • IL10 • IL6
November 09, 2020
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
(clinicaltrials.gov)
- P2; N=300; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Trial completion date: Jan 2022 ➔ Jan 2024
Clinical • Trial completion date • Immunology • Osteoarthritis • Pain • Rheumatology • MRI
October 22, 2020
Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis
(clinicaltrials.gov)
- P1/2; N=54; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Initiation date: Jul 2020 ➔ Nov 2020
Clinical • Trial initiation date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP
October 22, 2020
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19
(clinicaltrials.gov)
- P2; N=200; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Initiation date: Aug 2020 ➔ Nov 2020; Trial primary completion date: Aug 2021 ➔ Dec 2021
Clinical • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • CRP • CXCL8 • IL10 • IL6
October 20, 2020
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
(clinicaltrials.gov)
- P2; N=300; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Initiation date: Aug 2020 ➔ Nov 2020
Clinical • Trial initiation date • Immunology • Osteoarthritis • Pain • Rheumatology • MRI
July 14, 2020
Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19
(clinicaltrials.gov)
- P2; N=200; Not yet recruiting; Sponsor: Celltex Therapeutics Corporation; Trial primary completion date: Jul 2020 ➔ Aug 2021
Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • CRP • CXCL8 • IL10 • IL6
1 to 25
Of
27
Go to page
1
2